«Innovation and Regulation in the Pharmaceutical Industry»

Thursday, July 21 2016 | 17.30 h - 19.00 h | WWZ Auditorium

Summer Schoolin Law, Business & Economic Policy

17.30 Welcome: Prof. Rolf Weder(University of Basel, Faculty of Business and Economics)

17.35 A European Perspective: Prof. Herbert Zech(University of Basel, Faculty of Law)

17:50 A US Perspective: Prof. Catherine Sharkey(New York University, School of Law)

18.05 Panel Discussion: Prof. Stefan Felder, Moderator(University of Basel, Faculty of Business and Economics)

Catherine Sharkey, Herbert Zech,

Dr. Carlo Conti, Dr. Urs Jaisli

18.45 Questions from the Audience

19.00 Apéro

«Innovation and Regulation in the Pharmaceutical Industry»

Thursday, July 21 2016 | 17.30 h - 19.00 h WWZ Auditorium, Peter Merian-Weg 6, Basel

Program AbstractIntellectual property rights, regulation and liability form the legal framework in the pharmaceutical industry. Property rights strive to foster innovation as they provide financial incentives to firms, but sometimes run the risk of blocking further innovations. Regulatory law serves to protect consumers, but is increasingly used as a scheme for incentivizing clinical trials or the development of new specific pharmaceuticals like in pediatrics or for the treatment of rare diseases. Finally, liability rules allocate remaining risks. While strong liability rules may give adequate incentives for the development of safe pharmaceuticals and their appropriate marketing, they have to be aligned with intellectual property rights and regulatory rules in order to enhance the development of new pharmaceuticals.

Speakers:

Prof. Herbert Zech studied law at the Universities of Erlangen and Munich and obtained his doctorate degree (Dr. jur.) at the University of Constance. He also holds a degree in biology (Dipl.-Biol.) from Kaiserslautern University of Technology. Since April 2012 Herbert Zech has been teaching at the law faculty of the University of Basel. He currently holds the position of professor of life sciences law and intellectual property law and is also dean of research. His main fields of academic interest are intellectual property law, especially bio- and nanotechnology patents, information law and technology law.

Prof. Catherine Sharkey is the Crystal Eastman Professor of Law at New York University. She is a leading authority on the regulation of pharmaceuticals and federal preemption of state tort law. She studied law as well as economics and has published more than 40 articles, essays, and book chapters in the fields of torts, products liability, administrative law, remedies, and class actions. Sharkey is co-author with Richard Epstein of Cases and Materials on Torts (11th ed., 2016) and an adviser to the ALI Restatement Third, Torts: Liabi-lity for Economic Harm. She was the recipient of a Guggenheim Fellowship award in 2011-2012.

Prof. Rolf Weder is Professor of Economics and European Integration at the University of Basel. Since 2016, he is also Chairman of the Executive Committee of the Summer School in Law, Business and Economic Policy at the Faculty of Business and Economics of the University of Basel.

Prof. Stefan Felder studied Economics, Business Administration and Socio-logy, earned his PhD in 1989 und his habilitation in 1995 at the University of Bern. From 1997 to 2008 he was Associate Professor for Health Economics at the University of Magdeburg. In 2008 he became Full Professor of Econo-mics Duisburg-Essen University, Germany. Since 2011 he has been affiliated with the University of Basel, Switzerland, first as Associate Professor and since 2013 as Full Professor of Health Economics.

Panel: Dr. iur. Carlo Conti, attorney at law, is partner at the law firm WENGER PLATTNER. He advises institutions and organizations a wide range of issues of Life Sciences and Health Law. Furthermore, Dr. Carlo Conti is a member of the board of directors of several companies. During 15 years, Dr. iur. Carlo Conti was a member of the Government of the Canton of Basel-Stadt, Head of the Department of Public Health. He was president of the Swiss Conference of Cantonal Ministers of Public Health (GDK) and chairman of the board of SwissDRG AG.

Dr. Urs Jaisli Since March 1990 Dr. Urs Jaisli works in the Legal Department of the Roche Group in Basel. His current positions are Chief Compliance Officer of the Roche Group (since November 2008) and Head of Corporate Sus-tainability Committee (since June 2007). Dr. Jaisli is co-editor of the Basel Commentary on the Swiss Federal Law on Medical Products and Medical Devices, published in August 2006.

Welcome:

HOCHSTRASSEHOCHSTRASSE

PETER MERIAN-WEGPOSTPASSAGE PETER MERIAN-WEG

TRAMHALTESTELLE 15/E11GROSSPETERSTRASSE

TRAMHALTESTELLE 10 /11PETER MERIAN

NAUENSTRASSENAUENSTRASSE NAUENSTRASSE

JACOB BURCKHARDT HAUS PETER MERIAN-WEG 6PETER MERIAN HAUS

SBB – GLEISESBB – GLEISE

LONZAHOCHHAUS

POST

BAHNHOFBASEL

GU

ND

EL

IPA

SS

AR

EL

LE

GU

ND

EL

IPA

SS

AR

EL

LE

University of Basel Faculty of Business and Economics Peter Merian-Weg 6 4002 Basel Switzerland

wwz.unibas.ch

Educating Talentssince 1460.

Educating Talentssince 1460.